Vildagliptin
Template:Short description Template:Use dmy dates Template:Cs1 config Template:Main other <templatestyles src="Infobox drug/styles.css"/> Script error: No such module "Infobox".Template:Template otherScript error: No such module "TemplatePar".{{Infobox drug/maintenance categoriesTemplate:Yesno | drug_name = | INN = | _drugtype =
| _has_physiological_data= | _has_gene_therapy=
| vaccine_type= | mab_type= | _number_of_combo_chemicals=Script error: No such module "ParameterCount". | _vaccine_data= | _mab_data= | _mab_vaccine_data= | _mab_other_data=172532N#C[C@H]4N(C(=O)CNC13CC2CC(C1)CC(O)(C2)C3)CCC41S/C17H25N3O2/c18-9-14-2-1-3-20(14)15(21)10-19-16-5-12-4-13(6-16)8-17(22,7-12)11-16/h12-14,19,22H,1-8,10-11H2/t12?,13?,14-,16?,17?/m0/s1SYOKIDBDQMKNDQ-XWTIBIIYSA-NTemplate:StdinchiciteTemplate:StdinchiciteFreely Soluble in water | _combo_data= | _physiological_data= | _clinical_data=Template:Drugs.com Not recommendedBy mouthGalvus, othersA10,Template:ATC (with metformin) | _legal_data=[1]Rx-onlyPOMRx-only
| _other_data=(S)-1-[N-(3-Hydroxy-1-adamantyl)glycyl]pyrrolidine-2-carbonitrile
| _image_0_or_2 = Vildagliptin.svgVildagliptin-3D-balls.png | _image_LR =
| _datapage = Vildagliptin (data page) | _vaccine_target=_type_not_vaccine | _legal_all=POMRx-onlyRx-only | _ATC_prefix_supplemental=A10,Template:ATC (with metformin) | _has_EMA_link = | CAS_number=274901-16-5 | PubChem=6918537 | ChemSpiderID=5293734 | ChEBI= | ChEMBL=142703 | DrugBank=DB04876 | KEGG=D07080 | _hasInChI_or_Key=yes | UNII=I6B4B2U96P | _hasJmol02 = |_hasMultipleCASnumbers = |_hasMultiplePubChemCIDs = |_hasMultipleChEBIs =
| _countSecondIDs=Script error: No such module "ParameterCount". | _countIndexlabels=Script error: No such module "ParameterCount". | _trackListSortletter= |QID = |QID2 = |Verifiedfields=changed |Watchedfields=changed |verifiedrevid=470630169}}
Vildagliptin, sold under the brand name Galvus among others, is an oral anti-hyperglycemic agent (anti-diabetic drug) of the dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs.[1] Vildagliptin inhibits the inactivation of GLP-1[2][3] and GIP[3] by DPP-4, allowing GLP-1 and GIP to potentiate the secretion of insulin in the beta cells and suppress glucagon release by the alpha cells of the islets of Langerhans in the pancreas.
The most common side effects include dizziness.[1]
It was approved by the European Medicines Agency (EMA) in 2007.[4] The European Medicines Agency has also approved a combination of vildagliptin and metformin, vildagliptin/metformin (Eucreas by Novartis) as an oral treatment for type-2 diabetes.[5]
Vildagliptin has been shown to reduce hyperglycemia in type 2 diabetes mellitus.[2]
Medical uses
Vildagliptin is indicated, as an adjunct to diet and exercise, to improve glycemic control in adults with type 2 diabetes as monotherapy in people in whom metformin is inappropriate due to contraindications or intolerance; and in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycemic control.[1]
Adverse effects
The most common side effects include dizziness.[1]
References
Template:Navbox with collapsible groups Template:Portal bar Template:Authority control
- ↑ a b c d e Script error: No such module "citation/CS1". Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
- ↑ a b Script error: No such module "Citation/CS1".
- ↑ a b Script error: No such module "Citation/CS1".
- ↑ Script error: No such module "Citation/CS1".
- ↑ Script error: No such module "citation/CS1".